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Abstract
Liver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of
chronic liver injury often caused by viral infection and chemicals. Effective therapies against liver
fibrosis are still limited. In this review, we focus on research on Chinese medicines against liver
fibrosis in three categories, namely pure compounds, composite formulae and combination
treatment using single compounds with composite formulae or conventional medicines. Action
mechanisms of the anti-fibrosis Chinese medicines, clinical application, herbal adverse events and
quality control are also reviewed. Evidence indicates that some Chinese medicines are clinically
effective on liver fibrosis. Strict quality control such as research to identify and monitor the
manufacturing of Chinese medicines enables reliable pharmacological, clinical and in-depth
mechanism studies. Further experiments and clinical trials should be carried out on the platforms
that conform to international standards.
Background
Liver fibrosis is a condition of abnormal proliferation of
connective tissue due to various types of chronic liver
injury often caused by viral infection and chemicals. Hep-
atitis B viral (HBV) infection is the major cause of liver
fibrosis in China, whereas hepatitis C viral (HCV) infec-
tion and alcohol are the main causes in the United States,
Europe and Japan [1-4]. Liver fibrosis may progress into
liver cirrhosis and other complications coupled with car-
cinogenesis [5,6]. The pathogenesis of liver fibrosis
involves the activation of hepatic stellate cells (HSCs), the
over-expression and over-secretion of collagens, and con-
sequently an excessive accumulation of extracellular
matrix (ECM) proteins [7]. Research has been focused on
the management of liver fibrosis including the elimina-
tion of primary diseases, immunomodulation, suppres-
sion of hepatocyte inflammation, prevention of death and
damage of hepatocytes, inhibition of over-secretion and
accumulation of ECM proteins, promotion of ECM degra-
dation, improvement of microcirculation and metabo-
lism of liver and reduction of complications [8]. The
reversal of liver fibrosis and even cirrhosis has been docu-
mented [9].
Complementary and alternative treatments of liver fibro-
sis have been under active research worldwide [10-12]. In
Chinese medicine, liver fibrosis is thought to be caused by
'poor blood circulation, toxin stagnation and a deficiency
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of healthy energy' (dysregulated metabolism). Thus, Chi-
nese medicine therapy to treat liver fibrosis is mainly
based on reducing blood stagnation, resolving stasis,
eliminating toxins and enhancing body immunity.
This review aims to provide an overview on the types of
Chinese medicines used to treat liver fibrosis.
Chinese medicines used to treat liver fibrosis
Compounds and extracts
Around 20 compounds or extracts from Chinese medi-
cines have been reported to have liver protective and anti-
fibrotic effects. Various studies on their chemistry and
pharmacology as well as clinical trials have been carried
out to study these compounds or extracts. Table 1 summa-
rizes those with liver protection and anti-fibrotic effects
demonstrated in various research reports [13-68].
Composite formulae
More than ten composite formulae for liver fibrosis have
been reported [69-108]. Table 2 summarizes traditional
composite formulae such as Yinchenhao Tang, Xiao Chaihu
Tang, Buzhong Yiqi Tang and Renshen Yangrong Tang as well
as modern formulae such as Fufang Jinsane, Danshen Taox-
iong Tang, Ershen Zezhu Tang, Buqi Jianzhong Tang, Fangji
Tang, Handan Ganle, Ganzhifu and Fuzheng Huayu.
Combination therapy
Studies [109-118] show that combination therapy
improves clinical anti-fibrotic effects by using a single
compound with composite formulae or Chinese medi-
cines with conventional medicines (Table 3).
Action mechanisms of Chinese medicines in 
treating liver fibrosis
Inhibition of viral replication
HBV and HCV infections account for most liver cirrhosis
and primary liver cancer worldwide [6]. Certain Chinese
medicines are anti-HBV and anti-HCV. Berberine mark-
edly reduces viral production in vitro but is toxic to host
cells [51]. Artemisinin and artesunate strongly inhibit
viral production at concentrations that do not affect host
cell viability; artesunate and lamivudine exhibit synergis-
tic anti-HBV effects [51]. Another study shows that ascu-
cubin inhibits HBV replication [63]. Nobiletin, the active
ingredient of Citrus unshiu peel, has anti-HCV effects [94].
Clinical studies show that oxymatrine [28] is effective in
reducing hepatitis B viral replication in patients with
chronic hepatitis B. Xiao Chaihu Tang enhances produc-
tion of interferon-gamma (IFN-γ) and antibodies against
hepatitis B core and e antigen by peripheral blood mono-
nuclear cells (PBMC) in patients with chronic hepatitis
[82].  Handan Ganle inhibits viral DNA replication in
patients with decompensated cirrhosis thereby leading to
clinical improvement [102].
Immunomodulation action
Buzhong Yiqi Tang and  Renshen Yangrong Tang demon-
strate immunomodulation effects [91]. In a study on por-
cine serum-induced liver fibrosis in rats [92], Interleukin
13 (IL-13) levels are positively correlated with hydroxy-
proline (Hyp) contents in the liver. Buzhong Yiqi Tang and
Renshen Yangrong Tang significantly suppress the increase
of hepatic Hyp, while Xiao Chaihu Tang does not. Short-
term and long-term studies [93] show that Renshen Yan-
grong Tang is effective in liver fibrosis. Further studies find
that Renshen Yangrong Tang inhibits HCV infection, and
that Gomisin A, an active component in the formula's
Schisandra fruit, exhibits protective effects on immunolog-
ical hepatopathy [94].
Anti-oxidation and anti-inflammation actions
Salvia miltiorrhizae (Danshen) extract [13] improves serum
superoxide dismutase (SOD) activity and reduces
malondialdehyde (MDA) content in both carbon tetra-
chloride (CCl4) and dimethylnitrosamine (DMN)
induced hepatic fibrosis rat models. Salvia miltiorrhizae
extract [18] increases hepatic glutathione levels and
decreases peroxidation products in a dose-dependent
manner. Taurine [27,28] reduces oxidative stress and pre-
vents progression of hepatic fibrosis in CCl4-induced
hepatic damaged rats and inhibits transformation of the
hepatic stellate cell (HSC). In chronic ethanol-induced
hepatotoxicity or CCl4-induced rat liver fibrosis, Panax
notoginseng (Tianqi) extract or total saponin extracted from
Panax notoginseng reduces the generation of MDA, scav-
enges free radicals, increases liver and serum SOD content
and reduces the accumulation of body lipid peroxide [44-
46]. Ginkgo biloba (Yinxing) extract [49,50] and berberine
[54,55,60] exhibit anti-oxidation effects and suppress
nuclear factor κB (NF-κB) in rats or cell culture. Yinchen-
hao Tang is used to treat liver fibrosis and portal hyperten-
sion through suppressing the activated HSC function by
genipin, an absorbed form of its component, in CCl4-or
pig-serum- induced rat liver fibrosis [72]. Lin et al. [68]
find that the hepatoprotective effect of Solanum nigrum
Linn extract on CCl4-induced liver fibrosis is achieved
through blocking oxidative stress. Xiao Chaihu Tang
[76,83,85] whose active components baicalin and bai-
calein function as a potent fibrosis suppressant via the
inhibition of the oxidative stress in hepatocyte and HSC.
Handan Ganle [99] is effective in protecting against liver
fibrosis by inhibiting lipid peroxidation in hepatocytes
and HSC in vivo.
Regulation of cytokines, collagen metabolism and 
inhibition of HSC
The fibrogenic process is regulated by TGF-β1 and the spe-
cific blockade of TGF-β1/Smad3 signalling may therapeu-
tically intervene in the fibrosis of various tissues [119].
Most of the Chinese medicines listed in Tables 1 and 2Chinese Medicine 2009, 4:16 http://www.cmjournal.org/content/4/1/16
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Table 1: Anti-fibrosis effect of compounds or extracts derived from Chinese medicines
Compounds or extracts and major 
references
Pharmacological actions and clinical 
indications
Botanic source
Salvia miltiorrhiza
Extract & SA-B [13-18]
Reduce ALT and AST activities, inhibit protein 
expressions of TGF-β1, type I collagen and 
Smad3, anti-oxidation, down- regulate TGF-β1, 
TIMP-1 gene expression and MAPK activity, 
anti-nitric oxide, anti-apoptosis, apply to CHB 
patients
Root of Salviae miltiorrhiza Bge.
Glycyrrhizin [19-26] Reduce ALT and AST activities, inhibit NF-κB 
binding activity, down-regulate smurf2 gene 
expression, apply to CHC patients and prevent 
hepatocarcinoma in patients with HCV-
associated cirrhosis
Rhizome of Glycyrrhiza uralensis Fisch., 
Glycyrrhiza inflata Batal. or Glycyrrhiza glabra L.
Tetrandrine [27-32] Down-regulate c-fos and c-jun gene 
expression, anti-nitric oxide, up-regulate 
Smad7 gene expression, apply to CHB patients, 
down-regulate NF-κB signalling cascade and 
biomarker such as ICAM-1 and α-SMA
Root of Stephaniae tetrandrae S. Moore
Matrine & Oxymatrine [33-35] Inhibit PDGF and TGF-β1 actions, inhibit HBV-
DNA, improve liver function in patients with 
CHB or CHC patients
Root of Sophorae flavescentis Ait
Taurine [36,37] Inhibit TGF-β1 action, collagen formation in M 
cell culture system, reduce oxidative stress
Calculus Bovis
Tetramethylpyrazine
(Chuanxiongzine) [38]
Anti-oxidation, synergic anti-hepatic fibrosis 
effect with rehin, apply to CHB patients
Rhizome of Ligusticum chuanxiong Hort.
Rehin, emodin [39-41] Inhibit TGF-β1 expression, anti-HSC 
proliferation
Root and Rhizome of Rheum palmatum L., 
Rheum tanguticum Maxim. Ex Balf. or Rheum 
officinale Baill.
Curcumin [42,43] Anti-oxidative effect, activate PPARgamma to 
reduce cell proliferation, induce apoptosis and 
suppress ECM gene expression in vitro and in 
vivo
Rhizome of Curcumae longa L.
Panax Notoginseng saponin
and its water-extract [44-46]
Reduce AST and ALT, increase liver and serum 
SOD, reduce serum liver fibrosis markers 
levels, prevent liver fibrosis and hepatic 
microvascular dysfunction in liver fibrosis rats
Root of Panax notoginseng (Burk)F.H. Chen
Cordyceps polysaccharide [47,48] Increase CD4/CD8 T lymphocytes ratio and 
decrease HA and PC III, inhibit TGF-β1 and 
PDGF expressions, reduce AST and ALT, apply 
to CHB patients
The complex of the stroma of the fungus 
Cordceps sinensis (berk.)Sacc. and larva of 
caterpillar on which the fungus grows
Ginkgo biloba extract [49,50] Reduce ALT and AST, anti-oxidation, suppress 
NF-κB activation, inhibit TGF-β1 and collagen 
gene expression in rats
Leaves of Ginkgo bioba L.
Artemisinin/artesunate [51] As inhibitors of hepatitis B virus production Aerial part of Artemesia annua L.
Berberis aristata fruit extract and berberine 
[52-62]
Reduce AST and ALT, anti-oxidation, suppress 
expression of NF-κB, α-SMA, TGF-β1, anti-
liver cancer, induce apoptosis in cancer cell 
lines and animal models
Rhizome of Coptis chinensis French., Coptis teeta 
Wall., Coptis japonica Makino., other genus 
Berberis
Aucubin [63,64] Reduce AST and ALT, against HBV replication, 
suppress NF-κB activation in cell or animal 
models.
Ripe seed of Plantago asiatica L.
Ganoderma lucidum extract & Ganoderma 
polysaccharide [65,66]
Reduce AST, ALT, ALP, Tbil and the collagen 
content in rats with cirrhosis induced by biliary 
obstruction in rats, inhibit HSCs cells 
proliferation through blocking PDGFβR 
phosphorylation
Ganoderma lucidum
Gypenoside [67] Inhibits HSCs proliferation, arrest HSC cells at 
G1 phase, inhibit the signal pathway of PDGF-
Akt-p70 and down-regulate of cyclin D1 and 
D3 expression
Gynostemma pentaphyllum
Solanum nigrum Linn extract [68] Reduce AST, ALT, ALP, Tbil, modulate GSTs 
and SOD, repress the production of free 
radicals
Solanum nigrum LinnChinese Medicine 2009, 4:16 http://www.cmjournal.org/content/4/1/16
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exhibit in vitro and in vivo inhibitory effects on TGF-β1.
Salvianolic acid B (SA-B) inhibits HSC proliferation and
collagen production and decreases the cellular TGF-β1
autocrine and Mitogen-Activated Protein Kinase (MAPK)
activity, which may be the anti-fibrosis mechanism of SA-
B [14,17]. Paclitaxel, a compound isolated from Taxus
brevifolia, suppresses the TGF-β1 signalling pathway
between biliary epithelium cells and myofibroblasts and
reduces collagen synthesis [120]. Yinchenhao Tang [71]
regulates platelet-derived growth factor (PDGF)-BB-
dependent signalling pathways of HSC in primary culture
and attenuates the development of liver fibrosis induced
by thioacetamide in rats. Among the components of
Yinchenhao Tang, 3-methyl-1,6,8-trihydroxyanthraqui-
none (emodin) derived from Rhei rhizoma is the most
active compound [72]. Genipin, a metabolite derived
from  Yinchenhao Tang, suppresses wound-induced cell
migration and proliferation and decreases collagen type I,
TGF β1 and α-smooth muscle actins (α-SMA) mRNA and
protein expression [76]. Chen et al. [67] demonstrate that
Gypenosides inhibits PDGF-induced HSCs proliferation
through inhibiting the signalling pathway of PDGF-Akt-
p70S6K and down-regulating cyclin D1 and D3 expression.
Another study shows that ganoderic acids and ganode-
renic acids in Ganoderma lucidum (Lingzhi) extract signifi-
cantly inhibit the proliferation of HSCs by attenuating the
Table 2: Anti-fibrosis effect of composite formulae
Composite formulae and major 
references
Pharmacological actions and clinical 
indications
Compositions of formulae
Yinchenhao Tang [69-78] Induce HSCs apoptosis, inhibit HSCs activation, 
reduce collagen deposition and α-SMA and 
decrease the serum level of HA, apply to 
postoperative biliary atresia patients and icteric 
patients with cirrhosis
Herba Artemisiae Scopariae, Radix et Rhizoma 
Rhei, Fructus Gardeniae
Xiao Chaihu Tang [79-90] Inhibit TGF-β1 and PDGF expressions, regulate 
MMPs/TIMPs balance, increase IL-12 
production, suppress HSC activation, apply to 
CHC and CHB patients
Radix Bupleuri, Radix Scutellariae, Rhizoma 
Pinelliae, Radix Ginseng, Fructus Jujubae, Radix 
Glycyrrhizae
Buzhong Yiqi Tang [91,92] Immunoregulation, inhibit TGF-β1 and IL-13 
production, apply to CHC patients
Radix Astragali, Radix Glycyrrhizae, Radix Ginseng, 
Radix Angelicae Sinensis, Pericarpium citri 
reticulatae, Rhizoma Cimicifugae, Radix Bupleuri, 
Rhizoma Atractylodis macrocephalae
Renshen Yangrong Tang [92-94] Immunoregulation, inhibit TGF-β1 and IL-13 
production, apply to CHC patients
Radix Astragali, Radix Angelicae sinensis, Cortex 
Cinnamomi, Radix Glycyrrhizae, Pericarpium citri 
reticulatae, Rhizoma Atractylodis macrocephalae, 
Radix Ginseng, Radix Paeoniae alba, Radix 
Rehmanniae, Fructus Schisandrae chinensis, Poria, 
Cortex et Radix Polygalae
Fufang Jinsan E [95] Inhibit TGF-β1 and Smad3, Up-regulate Smad7 
in liver fibrotic rats
Radix Curcumae, Rhizoma Sparganii, Rhizoma 
Curcumae
Denshen Taoxiong Tang [96] Anti-ascites, regulate urine sodium 
concentration in liver fibrotic mouse
Radix Salviae Miltiorrhizae, Semen Persicae, 
Rhizoma Chuanxiong
Ershen Zezhu Tang [96] Anti-ascites, regulate urine sodium 
concentration in liver fibrotic mouse
Radix Codonopsis, Radix Salviae miltiorrhizae, 
Rhizoma Atractylodis macrocephalae, Rhizoma 
Alismatis
Buqi Jianzhong Tang [97,98] Diuretic effect, increase excretion Na+, reduce 
GPT and GOT, apply to cirrhosis ascites
Largehead Atractyloidis Rhizoma, Hoelen, Aurantii 
Nobilis Pericarpium, Radix Ginseng, Radix 
Scutellariae, Magnolia Bark, Alisma Rhizoma, Radix 
Ophiopogonis, Atractylodis Rhizoma
Fangji Tang [97,98] Diuretic effect, increase excretion Na+, reduce 
GPT and GOT, apply to cirrhosis ascites
Sinomeni Claulis Et Rhizoma, Mori Contex, Hoelen
Preilla Herba, Saussurae Radis
Handan Ganle [99-102] Anti-oxidatation, collagenolytic effect, regulate 
MMPs/TIMPs balance, apply to CHB patients
Radix Sophorae Flavescentis, Radix Salviae 
miltiorrhizae, Radix Paeoniae, Radix Astragali, 
Folium Ginkgo
Ganzhifu [103] Anti-oxidation, reduce collagens, anti-liver 
fibrosis in liver fibrotic rats
Rhizoma Zingiberis, Ramulus Cinnmomi, Radix 
Aconiti Lateralis preparata, Radix Astragali, Radix 
Bupleuri, Fructus Aurantii, Rhizoma Atractylodis 
macrocephalae, Radix Glycyrrhizae
Fuzheng Huay [104-108] Significantly decrease HA, LM, P-III-P and IV-C 
content, improve serum Alb, ALT, AST, GGT, 
LM, HA, Hyp and ration of BCAA/AAA in 
animals and CHB patients. Inhibit HSCs 
activation via FN/integrin signaling.
Radix Salvia miltiorrhizae, Cordyceps mycelia 
extract, Semen Persicae, Gynostemma 
Pentaphyllammak, Pollen Pini, Fructus schisandrae 
chinensisChinese Medicine 2009, 4:16 http://www.cmjournal.org/content/4/1/16
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blockade of PDGFβR phosphorylation [66]. Chen et al.
[88] show that 0.5 g/kg/day of Xiao Chaihu Tang signifi-
cantly reduces the serum level of the N-terminal pro-pep-
tide of collagen type III (PIII NP) and the mRNA
expression of TGF-β1 and PDGF in a rat bile duct ligated
model.
Anti-apoptosis in hepatocyte and inducement of apoptosis 
in HSC
Yamamoto et al. [73] find that Yinchenhao Tang inhibits
hepatocyte apoptosis induced by TGF-β1 in vitro. Another
study [74] demonstrates that pre-treatment with Yinchen-
hao Tang markedly suppresses liver apoptosis/injury. Gen-
ipin, which is a principal ingredient of Yinchenhao Tang,
suppresses Fas-mediated apoptosis in primary-cultured
murine hepatocytes in vitro [73]. The resistance to Ca2+-
induced mitochondrial permeability transition (MPT) is
enhanced in liver mitochondria of genipin-treated mice
[74]. These results suggest that the anti-apoptotic activity
of genipin via the interference with MPT is a possible
mechanism for the therapeutic effects of Yinchenhao Tang
and that Yinchenhao Tang and its ingredient genipin pro-
tect hepatocyte from liver apoptosis/injury. Conversely,
activated HSC plays a pivotal role in hepatic fibrosis, HSC
apoptosis is involved in the mechanisms of spontaneous
resolution of rat hepatic fibrosis, and the agent that
induces HSC apoptosis has been shown to reduce experi-
mental hepatic fibrosis in rats [121]. Considerable interest
has been generated in uncovering the molecular events
that regulate HSC apoptosis and discovering drugs that
can stimulate HSC apoptosis in a selective manner. Ikeda
et al. [75] find that Yinchenhao Tang induces HSC apopto-
sis in a time- and concentration-dependent manner as
judged by the nuclear morphology, quantitation of cyto-
plasmic histone-associated DNA oligonucleosome frag-
ments and caspase-3 activity. Thus, the induction of HSC
apoptosis may be the mechanism whereby Yinchenhao
Tang treats hepatic fibrosis. Tetrandrine [29] also induces
apoptosis of T-HSC/Cl-6 cells and induces the activation
of caspase-3 protease and subsequent proteolytic cleavage
of poly (ADP-ribose) polymerase.
Synergistic effects on liver fibrosis and carcinogenesis
Berberine derived from berberis markedly reduces viral
production in vitro [51]. In liver damage induced by para-
cetamol or CCl4, Berberis aristata fruit extract and berber-
ine, its principal ingredient, show hepato-protective
action [52,53]. Berberine also exhibits antioxidative
effects on tert-butyl hydroperoxide-induced oxidative
damage in rat liver [54] and in the lipopolysaccharide
(LPS) plus ischemia-reperfusion model [55]. Berberine
abolishes acetaldehyde-induced NF-κB activity and
cytokine production in a dose dependent manner, sug-
gesting the potential role of berberine to treat alcoholic
liver disease (ALD) [56]. In the rat liver fibrosis induced
by multiple hepatotoxic factors (CCl4, ethanol and high
cholesterol), the serum levels of ALT and AST and the
hepatic content of MDA and Hyp are markedly decreased,
while the activity of hepatic SOD is significantly increased
in berberine-treated groups in a dose-dependent manner.
In addition, histopathological changes, such as steatosis,
necrosis and myofibroblast proliferation, are reduced and
the expression of α-SMA and TGF-β1 is significantly
down-regulated in the berberine-treated groups [57].
Table 3: Anti-fibrosis effect of combinations of single compound and formulae or Chinese medicines and conventional medicines
Combination of drugs and major references Clinical indications and pharmacological actions or side effects
ITF-α. injection + glycyrrhizin (Stronger Neo Minophagen C) injection 
[109]
CHC patients. With IFN therapy, ALT levels did not decrease more 
than 50%, while with IFN combined with SNMC therapy, ALT levels 
decreased approximately 70% in all patients (one became normal), but 
no other parameters were changed.
Ursodeoxycholic acid P.O + glycyrrhizin P.O [110] CHC patients belong to interferon-resistant or unstable patients. 
Improving liver-specific enzyme abnormalities: AST, ALT and gamma-
glutamyl transpeptidase, no change HCV-related factors or liver 
histology compared with control.
Matrine injection + Xiao Chaihu Tang P.O [111] Liver fibrosis patients. Combination therapy improves AST, ALT and 
reduces HA, LN, CIV, TGF-β1 and TNF-α.
IFN-γ or IFN-α. injection + Xiao Chaihu Tang (Sho-saiko-to) P.O [112-
115]
CHB patients. Combination therapy improves AST, ALT, Tbil and has 
synergistic anti-fibrosis in biochemical parameters, but IFN and/or Sho-
saiko-to may also induce acute interstitial pneumonitis.
Tiopronin P.O + Xiao Chaihu Tang P.O [116] CHB patients. Synergistic effects in improving liver functions and fibrotic 
factors.
Lamivudine + Radix Salviae Miltiorrhizae [117] CHB patients. Treatment with both drugs was better than one and 
more effective than the control group in parameters of liver function 
and liver fibrosis.
Bushen Granule (BSG) P.O + Marine Injection (MI) [118] CHB patients. Combined treatment of BSG and MI was better than 
Lamivudine group in one year therapeutical course.Chinese Medicine 2009, 4:16 http://www.cmjournal.org/content/4/1/16
Page 6 of 11
(page number not for citation purposes)
Clinically, berberine has been used in Japan to alleviate
hypertyraminemia in patients with liver cirrhosis [58].
Berberine possesses anti-tumor effects in rats and mice
with chemical-induced liver cancer [59] and anti-invasion
in human lung cancer cell lines [60]. The mechanism may
be related to its anti-inflammation effects [60,61]. The
inhibitory effects of two different doses of berberine in
human liver cancer HepG2 cell lines display different
effects: in HepG2 cells treated with 24.0 mg/L of berber-
ine, an increase in the sub G0 phase that indicates cell
death is observed in cell cycle analysis with flow cytome-
try, however, there is no significant increase in sub G0 in
HepG2 cells treated with 4.0 mg/L of berberine [62].
These results demonstrate that the dosage of berberine is
a meaningful factor in liver diseases treatment. Composite
formulae, such as Xiao Chaihu Tang, not only inhibit viral
replication, ameliorate inflammation and enhance regen-
eration of hepatic cells, but also inhibit HSC proliferation,
suppress intra- and extra-cellular secretion, decrease the
secretion of collagen and promote its degradation and re-
absorption [79-90]. Shimizu et al. [83] show that Xiao
Chaihu Tang functions as a potent anti-fibrosis agent via
the inhibition of oxidative stress in hepatocytes and HSCs
and that its active components are baicalin and baicalein.
It should be noted that baicalin and baicalein are flavo-
noids with chemical structures very similar to silybinin
which possess anti-fibrogenic activities. Several composite
formulae have been used to improve ascites induced by
hepatic cirrhosis in chronic hepatitis B (CHB) or chronic
hepatitis C (CHC) patients. We demonstrate that Buqi
Jianzhong Tang and Fangji Tang increase Na+ excretion and
urine volume and reduce GOT and GPT in rats with CCl4-
induced liver damage [89,98]. Most of the Chinese medi-
cines in Tables 1 and 2 reduce serum enzymes, i.e. aspar-
tate transaminase (AST) and alanine transaminase (ALT).
A study with multivariate analysis demonstrates that the
mode of therapy and ALT levels are significant factors
affecting HCC development [26]. Glycyrrhizin adminis-
tered as Stronger Neo Minophagen C (SNMC) and Xiao
Chaihu Tang exhibit this effect [24-26,90] in long-term
clinical trials. Considered to possess anti-carcinogenic
properties, Xiao Chaihu Tang inhibits chemical hepatocar-
cinogenesis in animals, acts as a biological response mod-
ifier and suppresses the proliferation of hepatoma cells by
inducing apoptosis and arresting the cell cycle. Among the
active components of Xiao Chaihu Tang, baicalin, bai-
calein and saikosaponin have the ability to inhibit cell
proliferation [90].
Efficiency and safety of Chinese medicines in 
treating liver fibrosis
Efficacy
Some anti-fibrosis Chinese medicines, such as Salvianolic
acid B (SA-B), tetrandrine and oxymatrine, are clinically
effective. SA-B reverses liver fibrosis in chronic hepatitis B
patients. SA-B reduces the serum HA content and
decreases the overall serum fibrosis markers better than
IFN-γ [14]. A multi-centre, randomized, double-blind,
placebo-controlled clinical trial shows that oxymatrine
effectively reduces the DNA replication of HBV [34,35]
and the therapeutic effect is even stronger when used
together with Xiao Chaihu Tang [110]. A double-blind,
randomized, placebo-controlled phases I/II trial of intra-
venous glycyrrhizin for the treatment of chronic hepatitis
C shows that glycyrrhizin lowers serum ALT and that the
treatment has no effect on the RNA levels of HCV [23].
Long-term clinical trials in Japan and the Netherlands
demonstrate that interferon non-responder patients with
chronic hepatitis C and fibrosis stage 3 or 4 have a reduced
incidence rate of HCC after glycyrrhizin therapy normal-
izes ALT levels [24,25].
In China and Japan, many composite formulae are used to
treat liver fibrosis and cirrhosis (Table 2) and the pharma-
cological effects and mechanisms have been demon-
strated [69-94]. Experimental and clinical studies show
that Handan Ganle is effective [99-102]. Fuzheng Huayu,
another modern formula, has also been intensively stud-
ied [104-107]. The results suggest that Fuzheng Huayu's
anti-fibrosis effects may be associated with the inhibition
of liver collagen production [104]. Further study reveals
that the conditioned medium from activated HSC stimu-
lates the quiescent HSC proliferation and type I collagen
secretion and that the drug serum inhibits this stimulating
action and vascular endothelial growth factor (VEGF)
secretion from the activated HSC. Fuzheng Huayu acts
effectively against the autocrine activation pathway of
HSC [105].
A recent study demonstrates the action of Fuzheng Huayu
against HSC activation via the fibronectin/integrin-5β1
signalling pathway [107]. Another study shows that
Fuzheng Huayu alleviates liver fibrosis without any adverse
events [106]. A systematic review analyzes the efficacy and
safety of Fuzheng Huayu in treatment of CHB fibrosis
[108] based on clinical trials with placebo and/or random
control (other positive Chinese medicines and conven-
tional drugs). Seven studies on Fuzheng Huayu in the treat-
ment of CHB fibrosis (total 590 cases) are included in the
systematic review. This systematic review concludes that
Fuzheng Huayu has significant improvement of serum
fibrosis index and pathology of liver biopsy (class S in
fibrosis) without observable adverse events, although
some included studies are of low quality and are small
randomized clinical trials.
The combined therapy with ursodeoxycholic acid and gly-
cyrrhizin is safe and effective in improving liver-specific
enzyme abnormalities, and may be an alternative to inter-
feron in chronic hepatitis C viral infection, especially forChinese Medicine 2009, 4:16 http://www.cmjournal.org/content/4/1/16
Page 7 of 11
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interferon-resistant or unstable patients [110]. The antivi-
ral efficacy of Bushen granule (BSG) coupled with marine
injection (MI) to treat chronic hepatitis B was more effec-
tive than lamivudine treatment [118]. Other reports of
therapeutic value gained through combining conven-
tional and Chinese medicines can be found in Table
3[112-117].
Safety
There have been reports on adverse events and hepatotox-
icity caused by herbal medicines [122]. Xiao Chaihu Tang,
used alone or in combination with interferon, may induce
acute interstitial pneumonia in patients with chronic
active hepatitis [113,114]. Glycyrrhizin injection may
induce fatal biliary cirrhosis [123]. A one-year study dem-
onstrates that Chinese medicines caused hepatotoxicity in
patients with chronic hepatitis B [124]. Some of hepatic
veno-occlusive diseases have been ascribed to toxicity of
herbs; however, the toxic compounds remain to be deter-
mined. Hepatic veno-occlusive disease may result from
pyrrolizidine alkaloids which are found in numerous
plants worldwide. Systematic toxicological knowledge of
Chinese medicines is available [125].
Adverse events in the cases of herbal toxicity are in fact
very complex. The fatal biliary cirrhosis case [123] was a
Research chart of Chinese medicines for liver fibrosis Figure 1
Research chart of Chinese medicines for liver fibrosis. The re-evaluation involved in pharmaceutical and medical 
research including herb quality control, mechanism study and clinical trial will be carried out on standardized international plat-
forms.Chinese Medicine 2009, 4:16 http://www.cmjournal.org/content/4/1/16
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50-year-old woman suffering from a diffuse skin rash,
high fever and jaundice immediately after a second injec-
tion of glutathione and stronger neo-minophagen C,
which contains glycyrrhizin. It is difficult to determine the
cause of the adverse events to be indeed glycyrrhizin
(which is extracted from Glycyrrhiza uralensis) for the fol-
lowing reasons: (1) no literature has shown the hepato-
toxicity of glycyrrhizin until now; (2) stronger neo-
minophagen C includes 0.1% cysteine and 2.0% glycine
in physiological saline solution as well as 0.2% glycyr-
rhizin, and is also combined with glutathione; and (3) the
clinical indication of glycyrrhizin was clear enough (gly-
cyrrhizin is only used in chronic liver hepatitis without
bile duct obstruction, which is Yinchenhao Tang's indica-
tion in Chinese medicine clinical practice), and glycyr-
rhizin has no anti-fibrotic effect in rats with fibrosis
induced by bile duct ligation and scission [65].
Evidence against Chinese medicines
While ample evidence supports Chinese medicines in
treating liver fibrosis, some recent reviews on clinical trials
did not find significant effects. Levy et al. [126] review the
use of silymarin, glycyrrhizin, Xiao Chaihu Tang, Phyllan-
thus amarus, Picrorrhiza kurroa, Compound 861, CH-100
and LIV.52 used to treat chronic liver diseases. Dhiman et
al. [127] review Phyllanthus, Silybum marianum (milk this-
tle), glycyrrhizin and LIV.52 used to treat liver diseases.
However, neither review recommends the use of herbal
medicines to treat chronic liver diseases.
SA-B, Glycyrrhizin, Xiao Chaihu Tang and Yinchenhao Tang
are used to treat chronic liver diseases in China and Japan.
The major active herb is coptis, of which berberine is the
major active component [128]. According to Chinese
medicine theory, we use coptis to treat various liver dis-
eases and cancer in Hong Kong [129]. We also propose to
replace bear bile with coptis in Chinese medicine practice
[130].
Further studies on pharmacological actions and clinical
efficacies of the anti-fibrosis effects of Chinese medicines
are warranted. Systematic reviews to evaluate clinical stud-
ies on the efficacy and safety of Chinese medicines are also
necessary. An exemplifying strategy for these studies is
demonstrated in Figure 1.
Conclusion
Evidence indicates that some Chinese medicines are clin-
ically effective in treating liver fibrosis. Strict quality con-
trol of Chinese medicines is critical [131] for
pharmacological, clinical and in-depth mechanism stud-
ies [132]. Experiments and clinical trials should be carried
out on the platforms that conform to international stand-
ards [133].
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